Heron Therapeutics Files For Expanded Use Of Zynrelef In Soft Tissue, Orthopedic Surgical Procedures

• Heron Therapeutics Inc (NASDAQ: HRTX) has submitted a supplemental marketing application for Zynrelef (bupivacaine and meloxicam) extended-release solution to support the proposed indication for expanded use of Zynrelef in soft tissue and orthopedic surgical procedures.

• Zynrelef is currently indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot & ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

• Related: Analysts Cut Price Targets As Heron Therapeutics' Zynrelef Disappoints In Q3.

• The application also supports a newly passed congressional bill anticipated to provide separate reimbursement outside the package surgical payment for Zynrelef for almost three years between 1 January 2025 - 31 December 2027.

• In two Phase 3 trials, Zynrelef demonstrated the ability to significantly increase the proportion of patients taking no opioids after surgery.

• The company says separate payments from CMS are anticipated to accelerate the uptake of Zynrelef in large hospital systems significantly.

• Price Action: HRTX shares are up 6.00% at $2.39 on the last check Thursday.

See more from Benzinga

• FDA Authorizes TransCode's First-In-Human Clinical Trial With Solid Tumor Patients

• FDA Signs Off Hoth Therapeutics' Trial Application For HT-001 For Skin Cancers

• Much Wow! If You Invested $100 When Elon Musk First Tweeted About Dogecoin, Here's How Much You'd Have No

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.